Navigation Links
New Review Describes the use of Safinamide in Parkinson's Disease
Date:1/19/2017

LONDON, January 19, 2017 /PRNewswire/ --

New Review of Safinamide - A New Therapeutic Option to Address Motor Symptoms and Motor Complications in Mid- to Late-stage Parkinson's Disease

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

C Warren Olanow, Fabrizio Stocchi, European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late

Published recently in a supplement to European Neurological Review the peer-reviewed journal from touchNEUROLOGY, C Warren Olanow  et al, discusses a new therapeutic option in Parkinson's disease (PD). Levodopa is the cornerstone of therapy for PD and remains the most effective treatment available. Over time, however, the beneficial motor response to levodopa gradually shortens (this is known as 'wearing off') and motor complications (motor fluctuations and dyskinesias) increasingly affect so-called 'on-time'. The risk of developing motor complications is strongly linked to levodopa dose, independently of other predictive factors including disease severity. This provides a strong rationale for using other drugs, either alone or in combination with low-dose levodopa, to preserve the efficacy of levodopa for as long as possible. Several classes of drugs, including dopamine agonists, catechol-O-methyltransferase inhibitors, and monoamine oxidase B (MAO-B) inhibitors, are used as add-ons to levodopa, but all have significant drawbacks. Recently, safinamide (Xadago®) was approved for the treatment of PD patients as an add-on therapy to levodopa alone or in combination with other PD agents in mid- to late-stage fluctuating patients. Safinamide has a dual mechanism of action that includes modulation of dopaminergic metabolism through selective, reversible inhibition of MAO-B, and blockade of voltage and use-dependent sodium (Na+) channels, leading to inhibition of stimulated glutamate release. This article reviews the pathophysiology of PD and current treatment options, together with a comprehensive discussion of the pharmacokinetic, preclinical and clinical data relating to safinamide, including results from the 016/018 and the Safinamide in Idiopathic Parkinson's Disease With Motor Fluctuations, as add-on to Levodopa (SETTLE) studies and exploratory post hoc analyses. In these pivotal studies, safinamide 50-100 mg/day demonstrated efficacy in the treatment of motor fluctuations and motor symptoms in stabilised levodopa patients (improving the Unified Parkinson's Disease Rating Scale III score, and motor complications, as indicated by a significant reduction versus placebo in the primary endpoint of on-time without troublesome dyskinesias). Safinamide treatment was also effective for improving other motor complications (such as 'off-time', early-morning akinesia), motor symptoms, non-motor symptoms, activities of daily living and quality of life. These effects have been proved in the short term (six months) and maintained in the long term (24 months). Together, the data suggest that safinamide could be an appropriate choice as a first-line add-on therapy to levodopa in PD patients experiencing motor fluctuations.

The full peer-reviewed, open-access article is available here:

http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late

Disclosure: Fabrizio Stocchi receives consultant fees and honoraria for educational symposia from Zambon and has been a consultant to TEVA, Novartis, GSK, Lundbeck, Merck Serono, MSD, UCB, Chiesi Pharma, IMPAX, Newron, Zambon and Britannia. C. Warren Olanow receives consultant fees from Abbvie, Addex, Lundbeck, Newron, Novartis, Teva, Zambon. He is on the board for Michael J Fox Foundation, National Space Board Research Institute, Zambon. He has stock in Clintrex which provides consulting services for AstraZeneca, Accorda/Civitas, Biotie, Britannia, Corium, Cynapsus, Cytokinetics, Dart, EMD Serono, Flex, Forward, GeNeuro, Intec, Jazz, Melior, Michael J Fox Foundation, Lundbeck, Lysosomal Therapeutics, Medday, Neuroderm, Neuromedix, Neuropore, Osmotica, Otonomy, Otsuka/INC, Pfizer, Pharma2B, Prana, Raptor, Remedy, Sanofi/Genzyme, Serina, Sunovion, Synagile, Teva, Titan, Ultragenyx, Upsher Smith, US WorldMeds, Vaccinex, Weston Foundation.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

European Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:

Carla Denaro - Managing Editor

T: +44 (0) 207 193 6093

managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.


'/>"/>
SOURCE touchNEUROLOGY
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Anaphylaxis Pipeline Market Global Review Research for H2 2016
2. Canadian Addiction Recovery Network Reviews Fentanyl Crisis in Canada
3. U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
4. New Review of Taking a Clear View - Efficacy and Durability of Aflibercept in Neovascular Age-related Macular Degeneration
5. Ovarian Cancer - Pipeline Review, H2 2016
6. RxWiki Launches First Ever Patient Verified Reviews for 1400+ Pharmacy Brands
7. Post Operative Nausea And Vomiting - Pipeline Review, H2 2016
8. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016
9. Metastatic Breast Cancer - Pipeline Review, H2 2016
10. Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016
11. Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
Breaking Medicine News(10 mins):